[go: up one dir, main page]

TR201102067A1 - Valsartan and amlodipine combinations. - Google Patents

Valsartan and amlodipine combinations.

Info

Publication number
TR201102067A1
TR201102067A1 TR2011/02067A TR201102067A TR201102067A1 TR 201102067 A1 TR201102067 A1 TR 201102067A1 TR 2011/02067 A TR2011/02067 A TR 2011/02067A TR 201102067 A TR201102067 A TR 201102067A TR 201102067 A1 TR201102067 A1 TR 201102067A1
Authority
TR
Turkey
Prior art keywords
valsartan
amlodipine
combinations
average
particle size
Prior art date
Application number
TR2011/02067A
Other languages
Turkish (tr)
Inventor
Çi̇fter Ümi̇t
Tombayoğlu Vi̇ldan
Saydam Mehtap
Türkyilmaz Ali̇
Original Assignee
Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ filed Critical Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇
Priority to TR2011/02067A priority Critical patent/TR201102067A1/en
Priority to EP12157993A priority patent/EP2494964A1/en
Priority to EP12157992A priority patent/EP2494963A1/en
Publication of TR201102067A1 publication Critical patent/TR201102067A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Buluş direkt basılmış bir farmasötik tablet kombinasyon formülasyonu olup özelliği, 15-60 pm aralığında ortalama (d50) partikül büyüklüğüne sahip valsartan veya valsartanın farmasötik olarak kabul edilebilir bır tuzu ile 2 - 20 pm aralığında ortalama (d50) partikül büyüklüğüne sahip amlodipin veya amlodipinin farmasötik olarak kabul edilebilir bir tuzunu içermesi ile karakterize edilmektedir.The invention is a direct pressed pharmaceutical tablet combination formulation, characterized in that it is characterized by the combination of valsartan or a pharmaceutically acceptable salt of valsartan with an average (d50) particle size in the range of 15-60 pm and amlodipine or amlodipine with an average (d50) particle size in the range of 2-20 pm. characterized in that it contains an acceptable salt.

TR2011/02067A 2011-03-03 2011-03-03 Valsartan and amlodipine combinations. TR201102067A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2011/02067A TR201102067A1 (en) 2011-03-03 2011-03-03 Valsartan and amlodipine combinations.
EP12157993A EP2494964A1 (en) 2011-03-03 2012-03-02 Combinations of valsartan and amlodipine
EP12157992A EP2494963A1 (en) 2011-03-03 2012-03-02 Combinations of valsartan and amlodipine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2011/02067A TR201102067A1 (en) 2011-03-03 2011-03-03 Valsartan and amlodipine combinations.

Publications (1)

Publication Number Publication Date
TR201102067A1 true TR201102067A1 (en) 2012-09-21

Family

ID=45757339

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/02067A TR201102067A1 (en) 2011-03-03 2011-03-03 Valsartan and amlodipine combinations.

Country Status (2)

Country Link
EP (2) EP2494963A1 (en)
TR (1) TR201102067A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024251A1 (en) * 2015-08-06 2017-02-09 International Capital Investment Llc Disinfectant for drinkable water, food contact, industry, spas, swimming pools and air sterilization
EP3366291A1 (en) * 2017-02-22 2018-08-29 Montero Gida Sanayi Ve Ticaret A.S. Solid oral pharmaceutical compositions comprising alpha lipoic acid and water-soluble vitamins
TR201702630A2 (en) * 2017-02-22 2018-09-21 Montero Gida Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING ALPHA LIPOIC ACID AND WATER SOLUBLE VITAMINS
CN107823170B (en) * 2017-12-15 2020-07-07 湖南千金协力药业有限公司 Valsartan amlodipine tablet and preparation method thereof
CN107951849B (en) * 2017-12-15 2020-07-07 湖南千金协力药业有限公司 Amlodipine besylate tablet and preparation method thereof
CN109157526A (en) * 2018-09-13 2019-01-08 合肥合源药业有限公司 A kind of valsartan amlodipine compound preparation and its preparation process
CN109260169A (en) * 2018-10-30 2019-01-25 天津仁生医药科技有限公司 A kind of valsartan amlodipine tablet and preparation method thereof
CN110693847B (en) * 2019-12-07 2020-11-06 邹金林 Film-coated tablet for preventing and treating polycystic ovarian syndrome and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101647797A (en) * 2009-09-18 2010-02-17 海南锦瑞制药股份有限公司 Pharmaceutical composition containing Amlodipine besilate and valsartan and preparation method thereof
WO2011001440A1 (en) * 2009-07-03 2011-01-06 Hetero Research Foundation Pharmaceutical compositions of valsartan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
GT200600371A (en) 2005-08-17 2007-03-21 SOLID DOSE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD TO DO THE SAME
CN101468002A (en) * 2007-12-29 2009-07-01 北京瑞康医药技术有限公司 Therapeutic composition containing amlodipine salt and losartan medicine
US20110028456A1 (en) 2008-01-11 2011-02-03 Cipla Limited Solid Pharmaceutical Dosage Form
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
CN101507715B (en) * 2009-03-17 2011-11-16 严洁 Solid preparation of angiotensin receptor inhibitor and amlodipine and new preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011001440A1 (en) * 2009-07-03 2011-01-06 Hetero Research Foundation Pharmaceutical compositions of valsartan
CN101647797A (en) * 2009-09-18 2010-02-17 海南锦瑞制药股份有限公司 Pharmaceutical composition containing Amlodipine besilate and valsartan and preparation method thereof

Also Published As

Publication number Publication date
EP2494964A1 (en) 2012-09-05
EP2494963A1 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
TR201102067A1 (en) Valsartan and amlodipine combinations.
MX2016003754A (en) A stable pharmaceutical composition containing amlodipine and valsartan.
MX2021000550A (en) Tofacitinib oral sustained release dosage forms.
PH12015501439A1 (en) Oral care products comprising zinc oxide and trimethylglycine
IL235020A0 (en) N-phenyl benzenesulfonamide derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IN2015DN03984A (en)
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
WO2011104652A3 (en) Veterinary compositions
PT3003285T (en) Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity
ZA201509307B (en) Pharmaceutical composition, preparation and uses thereof
IL243786A0 (en) Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
WO2014114255A3 (en) Positioning, quick-release bioadhesion agent and use
BR112015002824A2 (en) compound, use of a compound, pharmaceutical composition, and combination pharmaceutical product.
CL2014003525A1 (en) Pharmaceutical composition comprising fimasartan, hydrochlorothiazide and a binder; preparation procedure; its use in the treatment of hypertension.
EA201400737A1 (en) DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE
EA201590405A1 (en) PREPARATION OF DRIED LIPOS FOR APPLICATION IN THE SYSTEMS OF THE ISSUE IN A PRESSED TYPE
MY174729A (en) Pharmaceutical combination drug
EA201491517A1 (en) N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DIHYDROXI-1-METHYL-2-OXO-3-HINOLINKARBOXAMID, ITS PREPARATION AND APPLICATION
EP3081375A4 (en) Stacked body, and gas barrier film
HRP20130082A2 (en) Pharmaceutical composition with sustained release of trimetazidine
HK1220390A1 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
EA201491510A1 (en) PHARMACEUTICAL COMPOSITION, ENJOYING IMPROVED STABILITY
PH12015500374A1 (en) Extended release compositions of an aminoalkyl nitrate
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat